EUVIMEDEUVIMED entdecken
Crossref

Antidiabetic drugs in myocardial infarction

Ján Murín

Súčasná klinická prax · 22.06.2026 · 23 (1) · 11-16

DOI: 10.48095/ccskp202611 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Súčasná klinická prax, online erschienen am 24.06.2026. Verfasst von Ján Murín.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prognosis of patients with acute myocardial infarction (AMI) improved with the arrival of early invasive coronary reperfusion and subsequent medication treatment. The new antidiabetic drugs in the last decade have shown their benefits in these patients, not only in diabetics but also in non-diabetics. This includes sodium-glucose co-transporter 2 (SGLT2) inhibitors, which protect organs damaged by diabetes, especially the heart and kidneys, but they are also effective in non-diabetic patients – prevention/treatment of heart failure, which tend to complicate AMI. We present data about the benefits of SGLT2 inhibitors in AMI, but data from three recent trials in patients shortly after AMI are also included. Another drug group, which is also looking for its place after AMI, are glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), because they are also useful in heart failure (mostly with preserved ejection fraction), but they also have a positive effect on risk factors (hypertension, diabetes, obesity). In heart failure, they suppress myocardial inflammation, which is an important mechanism of the progression of this form of heart failure. We also present results of recent clinical trials. New antidiabetic drugs are important drugs for patients after AMI, not only for diabetics since they have positive effects for atherosclerotic risk factors, but also for post-myocardial infarction heart failure.

Zitieren

APA

Murín, J. (2026). Antidiabetic drugs in myocardial infarction. Súčasná klinická prax, 23(1), 11-16. https://doi.org/10.48095/ccskp202611

Vancouver

Murín J. Antidiabetic drugs in myocardial infarction. Súčasná klinická prax. 2026;23(1):11-16. doi:10.48095/ccskp202611

BibTeX
@article{Murn2026,
  author = {Murín, Ján},
  title = {Antidiabetic drugs in myocardial infarction},
  journal = {Súčasná klinická prax},
  year = {2026},
  volume = {23},
  number = {1},
  pages = {11--16},
  doi = {10.48095/ccskp202611}
}
Kostenlos starten →